On November 4, 2020 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (ASH) (Free ASH Whitepaper) which will be held virtually from December 5-8, 2020 (Press release, Curis, NOV 4, 2020, View Source [SID1234569850]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased with the progress to date for our first-in-class IRAK4 kinase inhibitor, CA-4948 and are on track to report data by year-end for both our Phase 1 study in patients with non-Hodgkin’s lymphoma and our Phase 1 study in patients with acute myeloid leukemia and myelodysplastic syndromes," said James Dentzer, President and Chief Executive Officer of Curis. "In addition to the data published in the abstracts this morning, we look forward to providing updated safety and efficacy data at ASH (Free ASH Whitepaper) from both studies."
Details of the presentations are as follows:
Oral Presentation:
Title: Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
Author: Grzegorz S. Nowakowski, MD, Mayo Clinic
Session Name: 623. Mantle Cell and Indolent B-Cell Lymphoma – CAR-T and immunotherapy clinical studies
Session Date & Time: Monday, December 7, 2020, 1:30 pm – 3:00 pm ET
Presentation Time: 2:15 pm
Poster Presentation
Title: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Author: Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Session Date & Time: Monday, December 7, 2020, 10:00 a.m. – 6:30 p.m. ET
Poster Presentation
Title: A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a novel IRAK4 inhibitor CA-4948 in combination with ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
Author: Grzegorz S. Nowakowski, MD, Mayo Clinic
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma —Clinical Studies: Poster III
Session Date & Time: Monday, December 7, 2020, 10:00 a.m. – 6:30 p.m. ET
Additional meeting information can be found on the ASH (Free ASH Whitepaper) website at www.hematology.org/Annual-Meeting/. Each presentation will also be available under "Events and Presentations" in the Investors section of the Company’s website at www.curis.com